12.00pm AEDT Media Webcast Conference: ‘The A - Z of Recombinant COVID-19 Vaccine Manufacturing: An explainer’
(see end of release for details)
Since late last year, local manufacture of the AstraZeneca vaccine has been underway at CSL Behring’s advanced manufacturing facility in Broadmeadows, Victoria. This process employs 2000 litre bioreactors within which a host cell line is expanded and then used to produce the adenovirus-based vaccine developed by the University of Oxford. The vaccine is then purified and stored in preparation for the next stage of the process
On Monday, this next phase will commence at CSL’s Seqirus influenza vaccine facility in Parkville, Victoria.
The vaccine is formulated to a precise concentration, before being repeatedly filtered and filled into vials ahead of labelling and packing. At the same time, each batch of finished vaccine will undergo an extensive quality check process – by CSL, by AstraZeneca, and by the TGA.
Seqirus fill and finish will continue to run 24 hours a day, 7 days a week, with expected release of two million doses at the end of March, and then one million doses per week thereafter.
“Reaching this milestone would not have happened without around the clock work from our skilled team across both CSL Behring and Seqirus, with ongoing support from AstraZeneca. While the work isn’t over, we are incredibly proud to be on the cusp of delivering a locally made vaccine for Australians,” said Dr Andrew Nash, CSL’s Chief Scientific Officer.
“Some of the most critical work is still to come – in particular, extensive quality checks that will be behind every finished vaccine.
“We continue to be heartened by the extraordinary amount of scientific collaboration happening across industry, academia and government, as we all work towards the delivery of effective vaccines and therapies to address this pandemic.”
The AstraZeneca vaccine is currently being considered by the TGA for use in Australia. AstraZeneca will manage the application for registration for the vaccine on the Australian Register of Therapeutic Goods (ARTG). The Australian Government is responsible for all rollout and implementation of COVID-19 vaccination in Australia.
- ends -
B’roll is available here.
|Joanne Cleary||Christina Hickie|
|Senior Manager, Communications||Senior Manager, Communications|
|Phone: +61 428 816 751||Phone: +61 429 609 762|
12.00pm AEDT Media Webcast Conference
‘The A - Z of Recombinant COVID-19 Vaccine Manufacturing: An explainer’
Media are invited to join CSL for a technical briefing about the onshore manufacture of the AstraZeneca COVID-19 recombinant adenovirus vaccine (AZD1222), on Friday 12th February 2021 at 12.00pm, Australian Eastern Daylight Time (AEDT).
Hosted by the Australian Science Media Centre, representatives from CSL and Seqirus’ advanced manufacturing facilities located in Broadmeadows and Parkville will explain the process of manufacturing the AstraZeneca vaccine – starting from the first ‘vial thaw’ through to ‘harvest’ of the product in bulk, to formulation and ‘fill and finish’ into dose vials.
CSL has a contract to manufacture 50 million doses of the AstraZeneca vaccine for use by the Australian people and is on track to deliver first doses - tested, approved and released by the TGA (subject to TGA approval) – from late March.
Media activity is as follows:
12.00pm AEDT Media Webcast Conference
(AEDT: NSW, VIC, TAS, ACT / ACDT SA: 11.30am)
- Dr Susannah Eliot, CEO of the Australian Science Media Centre
- Dr Anthony Stowers, Senior Vice President, Recombinant Product Development, CSL
- Mr Chris Larkins, Senior Vice President, Global Operations, Seqirus
Participants can join the webcast conference by navigating to https://us02web.zoom.us/j/88311368611
About CSL: CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides life-saving products to more than 70 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSL
For more information about CSL Limited, visit www.csl.com.au